CY1119993T1 - Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης - Google Patents

Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης

Info

Publication number
CY1119993T1
CY1119993T1 CY20171101338T CY171101338T CY1119993T1 CY 1119993 T1 CY1119993 T1 CY 1119993T1 CY 20171101338 T CY20171101338 T CY 20171101338T CY 171101338 T CY171101338 T CY 171101338T CY 1119993 T1 CY1119993 T1 CY 1119993T1
Authority
CY
Cyprus
Prior art keywords
solid
surfactant
polymeric carrier
disconnectors
factors
Prior art date
Application number
CY20171101338T
Other languages
English (en)
Inventor
Esther RÖSCH
Peter Hoelig
David J. Lindley
Yeshwant D. Sanzgiri
Ping Tong
Original Assignee
Abbvie Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44903438&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119993(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Ireland Unlimited Company filed Critical Abbvie Ireland Unlimited Company
Publication of CY1119993T1 publication Critical patent/CY1119993T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μία προ-αποπτωτική διασπορά στερεού περιλαμβάνει, βασικά σε μη-κρυσταλλική μορφή, ανασταλτική ποσότητα πρωτεΐνης οικογένειας Bcl-2 του Τύπου I όπως ορίζεται στο παρόν, διασπαρμένη σε μία στερεά μήτρα που περιλαμβάνει (a) φαρμακευτικώς αποδεκτό υδατοδιαλυτό πολυμερικό φορέα και (b) φαρμακευτικώς αποδεκτό επιφανειοδραστικό. Μία μέθοδος για παρασκευής μιας τέτοιας διασποράς στερεού περιλαμβάνει υποβολή σε αυξημένη θερμοκρασία της ένωσης του Τύπου I, του υδατοδιαλυτού πολυμερικού φορέα και του επιφανειοδραστικού, για να παρέχεται εξωθήσιμο ημι-στερεό μίγμα· εξώθηση του ημι-στερεού μίγματος· και ψύξη του προκύπτοντος εξωθήματος για να παρέχει στερεά μήτρα που περιλαμβάνει τον πολυμερικό φορέα και το επιφανειοδραστικό και που έχει την ένωση διεσπαρμένη σε βασικά μη κρυσταλλική μορφή σε αυτή. Η διασπορά στερεού είναι κατάλληλη για χορήγηση από του στόματος σε ένα υποκείμενο που έχει ανάγκη αυτής, για θεραπεία ασθένειας που χαρακτηρίζεται από υπερέκφραση μιας ή περισσότερων αντι-αποπτωτικών Bcl-2 οικογένειας πρωτεϊνών, για παράδειγμα καρκίνου ή άνοσης ή αυτοάνοσης ασθένειας.
CY20171101338T 2010-10-29 2017-12-20 Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης CY1119993T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40852710P 2010-10-29 2010-10-29
PCT/US2011/054959 WO2012121758A1 (en) 2010-10-29 2011-10-05 Melt-extruded solid dispersions containing an apoptosis-inducing agent

Publications (1)

Publication Number Publication Date
CY1119993T1 true CY1119993T1 (el) 2018-12-12

Family

ID=44903438

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101338T CY1119993T1 (el) 2010-10-29 2017-12-20 Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης

Country Status (40)

Country Link
US (2) US20120108590A1 (el)
EP (3) EP4218731A3 (el)
JP (2) JP5902187B2 (el)
KR (2) KR101957137B1 (el)
CN (2) CN103282025B (el)
AR (2) AR083656A1 (el)
AU (1) AU2011361704B2 (el)
BR (1) BR112013010524A8 (el)
CA (1) CA2813985C (el)
CL (1) CL2013001120A1 (el)
CO (1) CO6781472A2 (el)
CR (2) CR20180289A (el)
CY (1) CY1119993T1 (el)
DK (1) DK2613769T3 (el)
DO (2) DOP2013000092A (el)
EC (2) ECSP13012647A (el)
ES (1) ES2647583T3 (el)
GT (1) GT201300102A (el)
HK (1) HK1243761A1 (el)
HR (1) HRP20171884T1 (el)
HU (1) HUE035169T2 (el)
IL (2) IL226215A (el)
LT (1) LT2613769T (el)
ME (1) ME02942B (el)
MX (2) MX362113B (el)
MY (1) MY189224A (el)
NO (1) NO2613769T3 (el)
NZ (1) NZ608907A (el)
PE (2) PE20171242A1 (el)
PL (1) PL2613769T3 (el)
PT (1) PT2613769T (el)
RS (1) RS56718B1 (el)
RU (2) RU2577859C2 (el)
SG (2) SG189477A1 (el)
SI (1) SI2613769T1 (el)
TW (2) TWI648261B (el)
UA (1) UA113500C2 (el)
UY (3) UY39192A (el)
WO (1) WO2012121758A1 (el)
ZA (2) ZA201302669B (el)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
SG10201801794WA (en) 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
LT2643322T (lt) 2010-11-23 2018-01-10 Abbvie Inc. Apoptozę skatinančio agento druskos ir kristalinės formos
UA119150C2 (uk) 2010-11-23 2019-05-10 Еббві Айрленд Анлімітед Компані СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2
US20140189897A1 (en) 2011-06-21 2014-07-03 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
RU2014128010A (ru) 2011-12-13 2016-02-10 Бак Инститьют Фо Рисерч Он Эйджин Способы улучшения средств консервативной терапии
WO2013158664A2 (en) 2012-04-17 2013-10-24 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
US9901081B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse for determining the role of senescent cells in cancer
US9901080B2 (en) 2012-08-23 2018-02-27 Buck Institute For Research On Aging Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
EP3919079A1 (en) 2012-09-07 2021-12-08 Genentech, Inc. Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
JP6275726B2 (ja) * 2012-09-27 2018-02-07 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
EP4019491A1 (en) 2013-03-13 2022-06-29 AbbVie Ireland Unlimited Company Process for preparing a synthetic intermediate useful in the preparation of an apoptosis-inducing agent
AR095265A1 (es) 2013-03-13 2015-09-30 Abbvie Inc Procesos para la preparación de un agente inductor de la apoptosis
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
CA3100140C (en) 2014-01-28 2023-10-24 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
AU2015214502B2 (en) * 2014-02-05 2019-06-06 Merck Sharp & Dohme Llc Tablet formulation for CGRP-active compounds
US9238652B2 (en) 2014-03-04 2016-01-19 Abbvie Inc. Processes for the preparation of an apoptosis-inducing agent
LT3179991T (lt) 2014-08-11 2021-11-10 Acerta Pharma B.V. Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai
WO2016031651A1 (ja) 2014-08-29 2016-03-03 花王株式会社 難溶解性ポリフェノール類を含有する固体分散体の製造方法
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
GB201502073D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
MX2018005233A (es) 2015-11-03 2019-04-29 Genentech Inc Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
CN106957315B (zh) * 2016-01-08 2019-08-13 中国人民解放军第二军医大学 N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN109563096A (zh) * 2016-06-09 2019-04-02 雷迪博士实验室有限公司 固体形式的维奈托克和用于制备维奈托克的方法
WO2018009444A1 (en) * 2016-07-06 2018-01-11 Concert Pharmaceuticals, Inc. Deuterated venetoclax
CN107648185A (zh) * 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
US10800777B2 (en) 2016-10-14 2020-10-13 Mylan Laboratories Limited Polymorphic forms of VENCLEXTA
EP3333167A1 (en) * 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
EP3565815B1 (en) * 2017-01-07 2024-03-13 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
LT3612531T (lt) 2017-04-18 2022-09-26 Shanghai Fochon Pharmaceutical Co., Ltd. Apoptozę sukeliančios medžiagos
KR20200092308A (ko) 2017-08-23 2020-08-03 뉴에이브 파마슈티칼 인크. Bcl-2 억제제
WO2019135253A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Polymorphic forms of venetoclax
MX2020007392A (es) 2018-01-10 2020-10-14 Recurium Ip Holdings Llc Compuestos de benzamida.
WO2020023435A1 (en) 2018-07-24 2020-01-30 Albany Molecular Research, Inc. Venetoclax basic salts and processes for the purification of venetoclax
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
US20220339141A1 (en) 2019-09-18 2022-10-27 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
US20230295183A1 (en) * 2020-02-24 2023-09-21 Newave Pharmaceutical Inc. Hot melt extruded solid dispersions containing a bcl2 inhibitor
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
AU692506B2 (en) 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6277985B1 (en) 1995-09-15 2001-08-21 Pharmacia & Upjohn Company Aminoaryl oxazolidinone N-oxides
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN101712720A (zh) 1996-02-09 2010-05-26 艾博特生物技术有限公司 结合人TNFα的人抗体
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
BE1011899A6 (fr) 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
KR20010083092A (ko) 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
CN1217936C (zh) 1999-12-28 2005-09-07 卫材株式会社 含有磺酰胺的杂环化合物
US20060183776A9 (en) 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
BR0116845A (pt) 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados éter úteis como inibidores de isozimas pde4
US6927009B2 (en) 2001-05-22 2005-08-09 Fuji Photo Film Co., Ltd. Positive photosensitive composition
AU2002259204B2 (en) 2001-06-06 2008-01-17 Eli Lilly And Company Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DE60332212D1 (de) 2002-02-04 2010-06-02 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator
WO2003072139A1 (en) 2002-02-26 2003-09-04 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
IL163689A0 (en) 2002-02-26 2005-12-18 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound zd1839
FR2836914B1 (fr) 2002-03-11 2008-03-14 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
MY129850A (en) 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
US7307163B2 (en) 2004-04-19 2007-12-11 Symed Labs Limited Process for the preparation of linezolid and related compounds
US7318503B2 (en) 2004-04-26 2008-01-15 Akebono Corporation (North America) Pad retaining clips
JP2007536299A (ja) 2004-05-04 2007-12-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｌｔｂ４アンタゴニトを含有する固形医薬形態
EP1768967B1 (en) 2004-07-20 2009-04-22 Symed Labs Limited Novel intermediates for linezolid and related compounds
ATE395905T1 (de) 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
FR2875409B1 (fr) 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI337608B (en) 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
WO2006124863A2 (en) 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7863288B2 (en) 2005-06-22 2011-01-04 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
WO2007043057A2 (en) 2005-10-11 2007-04-19 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CN101346128B (zh) 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
US7151188B1 (en) 2005-11-16 2006-12-19 General Electric Company Process for the production of mercaptoalkylalkoxysilanes
EP2037912A2 (en) 2006-05-15 2009-03-25 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
JP2009542664A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増大させる置換されたピペリジンの使用の方法
CN101511800B (zh) 2006-07-14 2013-02-27 坎莫森特里克斯公司 三唑基苯基苯磺酰胺
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
JP5546860B2 (ja) 2006-08-16 2014-07-09 ノバルティス アーゲー 高結晶性治療化合物の固体分散体を製造するための方法
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
MX2009004861A (es) 2006-11-09 2009-05-21 Abbott Gmbh & Co Kg Forma de dosificacion farmaceutica para la administracion oral de inhibidor de tirosina quinasa.
US20080181948A1 (en) * 2006-11-15 2008-07-31 Abbott Laboratories Solid pharmaceutical dosage formulations
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
KR101222412B1 (ko) 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
RU2351352C2 (ru) 2007-04-09 2009-04-10 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Твердая нанокомпозиция для доставки биологически активных веществ
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
KR20100012031A (ko) 2007-04-19 2010-02-04 콘서트 파마슈티컬즈, 인크. 중수소화된 모르폴리닐 화합물
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
US20090131485A1 (en) 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
AU2008307565A1 (en) 2007-10-01 2009-04-09 The Johns Hopkins University Methods of treating neurological autoimmune disorders with cyclophosphamide
WO2009045476A1 (en) 2007-10-02 2009-04-09 Concert Pharmaceuticals, Inc. Pyrimidinedione derivatives
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2212298B1 (en) 2007-10-18 2013-03-27 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
RU2526201C2 (ru) 2007-11-16 2014-08-20 Эббви Инк. Способ лечения артрита
CA2708223A1 (en) 2007-12-06 2009-06-11 Andrew Krivoshik Oral compositions of abt-263 for treating cancer
KR20100113112A (ko) 2008-01-15 2010-10-20 아보트 러보러터리즈 개선된 포유동물 발현 벡터 및 이의 용도
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CN101548960B (zh) 2008-04-01 2012-11-07 沈阳药科大学 高溶出度口服联苯双酯胶囊及其制备方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
ES2588374T3 (es) * 2008-12-05 2016-11-02 Abbvie Inc. Derivados de sulfonamidas como agentes inductores de la apoptosis selectivos para bcl-2 para el tratamiento del cáncer y enfermedades inmunitarias
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20110245156A1 (en) 2008-12-09 2011-10-06 Cytokine Pharmasciences, Inc. Novel antiviral compounds, compositions, and methods of use
US8959548B2 (en) * 2008-12-22 2015-02-17 Verizon Patent And Licensing Inc. Presenting advertisements with video program descriptions
WO2010072734A2 (en) 2008-12-23 2010-07-01 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
SI2511264T1 (sl) * 2009-01-19 2015-07-31 Abb Vie Inc. Sredstva za induciranje apoptoze za zdravljenje raka ter imunskih in avtoimunskih obolenj
CA2747837A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US20100297194A1 (en) 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US20100278921A1 (en) 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20190086591A (ko) * 2009-05-26 2019-07-22 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
NZ591973A (en) 2009-06-11 2013-03-28 Abbott Lab Anti-viral compounds to treat hcv infection
JP2012530704A (ja) 2009-06-18 2012-12-06 アボット・ラボラトリーズ 安定なナノ粒子状薬物懸濁液
RU2551376C2 (ru) 2009-09-20 2015-05-20 Эббви Инк. Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
SG10201801794WA (en) 2010-10-29 2018-04-27 Abbvie Inc Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
UA119150C2 (uk) 2010-11-23 2019-05-10 Еббві Айрленд Анлімітед Компані СПОСОБИ ЛІКУВАННЯ З ВИКОРИСТАННЯМ СЕЛЕКТИВНИХ ІНГІБІТОРІВ Всl-2
LT2643322T (lt) 2010-11-23 2018-01-10 Abbvie Inc. Apoptozę skatinančio agento druskos ir kristalinės formos
EP2776603B1 (en) 2011-11-11 2019-03-06 SiO2 Medical Products, Inc. PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS

Also Published As

Publication number Publication date
JP6153638B2 (ja) 2017-06-28
US20150148331A1 (en) 2015-05-28
UY33692A (es) 2012-04-30
RU2633353C1 (ru) 2017-10-12
KR20140052921A (ko) 2014-05-07
KR20180024025A (ko) 2018-03-07
IL226215A0 (en) 2013-07-31
ES2647583T3 (es) 2017-12-22
HRP20171884T1 (hr) 2018-01-12
KR101957137B1 (ko) 2019-03-13
CA2813985C (en) 2019-01-15
ZA201401440B (en) 2015-06-24
HUE035169T2 (en) 2018-05-02
DOP2013000092A (es) 2013-09-30
SG189477A1 (en) 2013-05-31
ME02942B (me) 2018-04-20
LT2613769T (lt) 2018-02-12
GT201300102A (es) 2014-05-20
IL226215A (en) 2017-05-29
DOP2017000003A (es) 2017-04-16
EP4218731A2 (en) 2023-08-02
EP2613769A1 (en) 2013-07-17
AR122475A2 (es) 2022-09-14
PE20140381A1 (es) 2014-04-21
BR112013010524A8 (pt) 2018-06-12
DK2613769T3 (en) 2018-01-08
CN108175749B (zh) 2021-09-10
PE20171242A1 (es) 2017-08-24
UY39192A (es) 2021-06-30
CL2013001120A1 (es) 2013-10-04
TWI648261B (zh) 2019-01-21
IL251877B (en) 2019-03-31
RS56718B1 (sr) 2018-03-30
MX2013004843A (es) 2013-10-01
JP5902187B2 (ja) 2016-04-13
SI2613769T1 (en) 2018-02-28
CR20130224A (es) 2013-06-12
WO2012121758A1 (en) 2012-09-13
SG2014015077A (en) 2014-04-28
CA2813985A1 (en) 2012-09-13
PL2613769T3 (pl) 2018-04-30
EP4218731A3 (en) 2023-08-16
JP2013544804A (ja) 2013-12-19
ECSP13012647A (es) 2013-07-31
TW201636324A (zh) 2016-10-16
NZ608907A (en) 2015-05-29
EP3219308A1 (en) 2017-09-20
NO2613769T3 (el) 2018-02-24
RU2013124823A (ru) 2014-12-10
UY37326A (es) 2019-02-28
CN103282025B (zh) 2018-01-02
ZA201302669B (en) 2014-10-29
CR20180289A (es) 2018-06-26
AU2011361704B2 (en) 2015-10-01
AU2011361704A1 (en) 2013-05-02
CN103282025A (zh) 2013-09-04
MX362113B (es) 2019-01-07
CO6781472A2 (es) 2013-10-31
KR101836820B1 (ko) 2018-03-09
US11369599B2 (en) 2022-06-28
TWI535699B (zh) 2016-06-01
EP2613769B1 (en) 2017-09-27
ECSP22086925A (es) 2023-01-31
BR112013010524A2 (pt) 2016-08-02
MX345603B (es) 2017-02-03
MY189224A (en) 2022-01-31
TW201242946A (en) 2012-11-01
PT2613769T (pt) 2018-01-04
CN108175749A (zh) 2018-06-19
AR083656A1 (es) 2013-03-13
HK1243761A1 (zh) 2018-07-20
JP2016147878A (ja) 2016-08-18
UA113500C2 (xx) 2017-02-10
RU2577859C2 (ru) 2016-03-20
IL251877A0 (en) 2017-06-29
US20120108590A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
CY1119993T1 (el) Εξωθουμενες με τηξη διασπορες στερεου που περιεχουν παραγοντα διεγερσης αποπτωσης
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
CY1121230T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν οξειδιο-υδροξειδιο του σιδηρου
MX349533B (es) Dispersiones solidas que contienen un agente inductor de apoptosis.
BR112015032736A2 (pt) inibidores de bromodomínio cristalino
MY157661A (en) Bendamustine pharmaceutical compositions
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ606194A (en) Isoxazoline derivatives as antiparasitic agents
BR112013004865A2 (pt) lípidos adequados para entrega lipossomal de codificadores de proteínas rna
BR112012016021A8 (pt) Formulações estáveis para liofilização de partículas terapêuticas
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
EA201170962A1 (ru) Препарат разагилина с отсроченным высвобождением действующего вещества
SV2011003888A (es) Compuestos que expanden las celulas madre hematopoieticas
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
CY1113422T1 (el) Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842
BR112012006252A2 (pt) "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
BRPI1012959A8 (pt) Dispersoes solidas contendo um agente promotor de apoptose
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
UA94036C2 (ru) Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
MX2011011525A (es) Formulacion lipida estabilizada de promotor de apoptosis.
EA201690005A1 (ru) Состав с модифицированной кинетикой высвобождения
CL2008001325A1 (es) Compuestos derivados de pirazol-piridinona; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar inflamacion, enfermedad de paget, osteoartritis, alzheimer, entre otras enfermedades.
MX2015006862A (es) Vacuna para enfermedad intrauterina.
AR084095A1 (es) Peptidos tomm34 y vacunas que los incluyen
BRPI0705822A2 (pt) formulação injetável com ação prolongada e uso de um agente semi-sintético derivado do grupo das avermectinas, em combinação com um polìmero biodegradável